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eligible for surgery, shows that HA viscosupplementation has the most favorable 
outcome, both from a clinical and economic point of view.
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Objectives: European registries of Rheumatoid Arthritis (RA) patients treated by 
biological agents suggest that 70-80% are maintained in first line at 1 year despite 
potential insufficient efficacy. Post hoc analyses of certolizumab pegol (CZP) stud-
ies indicate that a 3 month clinical response had a high predictive value of the 1 
year outcome. The objective was to examine the efficiency of a strategy consisting 
of early switching from CZP to a second line TNF inhibitor in case of insufficient 
clinical response at 3 months (3M) in the French setting versus current clinical 
practices. MethOds: A decision-tree model was built to estimate the clinical 
outcomes (ACR50 cumulated time) and the direct costs of different cohorts of RA 
patients over a 2 year period. ACR50 was considered as an RA satisfying clinical 
outcome. The “3M tight control” strategy consisted of stopping CZP at 3 months in 
patients not achieving the ACR50 criterion and switching them to other biologics. 
Three reference cohorts treated with first line CZP, etanercept or adalimumab, 
respectively, according to current clinical practices were considered as compara-
tors (reference). All TNF inhibitors were assumed to have equal efficacy in first line. 
Costs were estimated at 2013 French public prices. Results: The proportion of 
patients achieving ACR50 after a 2 year follow-up was 58% in all reference cohorts 
and 75% in the “3M tight control” CZP strategy cohort. The costs per patient-year 
in ACR50 were € 19,326 with the “3M tight control” strategy cohort and € 23,588, 
€ 26,774 and € 30,285 for the CZP, etanercept and adalimumab reference cohorts, 
respectively. The strategy “3M tight control” had an incremental cost-effectiveness 
ratio of € 5,605/patient-year in ACR50 versus CZP reference, and was dominant 
versus etanercept or adalimumab reference. cOnclusiOns: A 3-month tight con-
trol management of RA patients with CZP as first line treatment is cost-effective 
compared to alternatives.
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Objectives: To conduct a cost-per-responder analysis of biologic treatments 
(adalimumab, etanercept, golimumab, and infliximab) for the treatment of active 
ankylosing spondylitis (AS) from the German Statutory Health Insurants (SHI) 
perspective. MethOds: A systematic literature review was conducted to identify 
randomized clinical trials for biologic treatments for active AS. The clinical efficacy 
of biologic therapies and standard of care was evaluated using Assessment of 
SpondyloArthritis international Society (ASAS) 20 response, which is defined as at 
least 20% improvement from baseline using ASAS criteria. The relative probability 
of achieving ASAS 20 at Week 12 with each biologic therapy was estimated via net-
work meta-analysis. Evaluation was conducted in terms of cost-per-incremental 
ASAS 20 responder. Twelve-week costs were assessed in terms of 2012 euros, and 
included drug acquisition, administration, laboratory tests, and clinic visits based 
on German treatment guidelines. Weight-based dosing for infliximab assumed 
an average weight of 78.6 kg. Results: Thirteen randomized controlled trials of 
active AS with a minimal duration of 12 weeks were identified; 10 reported ASAS 
20 at Week 12. The estimated rates of ASAS 20 response at Week 12 were not sta-
tistically different between infliximab (70.8%), adalimumab (62.9%), golimumab 
(61.2%), and etanercept (60.5%). However, all 4 biologic therapies were significantly 
better than the standard of care (27.1%). In the base case, adalimumab had the 
lowest cost-per-incremental ASAS 20 responder compared with standard of care 
(€ 13,282 per incremental ASAS 20 responder), followed by golimumab (€ 13,947), 
etanercept (€ 14,221), and infliximab (€ 22,838). These rankings were unchanged 
in sensitivity analyses based on ASAS 40 response rates (estimated from 6 tri-
als). cOnclusiOns: All 4 biologic treatments were more efficacious in terms of 
ASAS 20 response than the standard of care. Among biologics, adalimumab showed 
the lowest cost per incremental ASAS 20 responder at Week 12 for active AS from 
the German SHI perspective.
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Objectives: To assess the cost-effectiveness of rituximab and anti-TNF-alfa 
agents in the treatment of Russian patients with rheumatoid arthritis (RA) who 
failed previous anti-TNF-alfa therapy. MethOds: The pharmacoeconomic model 
was developed based on the data from multicentre prospective 3-year observa-
tional MIRAR-study (J. Gomez-Reino et al., 2012). A one-year time horizon was 
adopted in the model. The cost analysis included costs of medicines and expenses 
for the day care services. The efficacy of therapies was defined as a reduction of 
disease activity score in 28 joints (DAS28) and proportion of patients achieved 
EULAR good or moderate response after 6, 9 and 12 months since biological 
therapy was started. To assess the robustness of the results, one-way sensitivity 
analysis (SA) was carried out. Results: Treatment with rituximab was associated 
significantly observed among patients who switched during their TNF-α antago-
nist treatment. cOnclusiOns: RA with biological treatment was associated with 
reductions of service uses; however, overall service costs were compromised by 
costs incurred from increased utilization of outpatient service and TNF-α antagonist 
medication costs under the context of health care in Taiwan.
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Objectives: Multicentric, open, retrospective study to determine whether NSAID 
consumption may be reduced by the use of US-guided Intra-articular injection 
(USGIAI) of hyaluronic acid (HA), in hip joint in patients affected by symptomatic 
hip OA. MethOds: Patients affected by mono or bilateral hip OA entered the study 
and were administered with a single HA (HyalOne-Hyalubrix 60) injection every six 
months. As primary endpoint, consumption of NSAIDs was evaluated by recording 
the number of days a month the patient used NSAID during the month previous to 
the visit, reported at each visit during the 24 months follow-up period, while second-
ary endpoints was represented by the percentage of patients assuming NSAIDs at 
baseline and at each control visit. Results: A total of 755 patients entered the study 
from 2008 to 2013. Consumption of NSAIDs was reduced from a consumption rate 
mean of 21,3 to a mean of 5,08 at the third month; this reduction further improved 
at 12th and 24th month with a reduction respectively to 4,14 and 3,79. Percentage 
of patients not taking NSAIDs at baseline was 45%; this percentage raised to 57% at 
12 months and remained stable (58%) at 24 months. We performed an evaluation of 
costs of therapies for hip OA for two hypothetic populations of 1000 patients each, 
the first one undergoing to HA USGIAI every six months for a total of 4 injections 
in 2 years, and the second one of 1000 patients undergoing to chronic daily NSAIDs 
therapy, both for two years. Our results confirmed in the USGIAI population a cost 
savings in comparison with the NSAIDs population. cOnclusiOns: HA USGIAI, 
administered every 6 months, reduce the assumption of NSAIDs in patients affected 
by hip OA, reflecting its efficacy on pain relief and cost saving.
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Objectives: To determine the clinical and pharmacoeconomic indicators from 
pharmacotherapeutic monitoring of patients using immunobiological (IMB) in 
a Health Insurance Company in Fortaleza - Brazil. MethOds: Cross-sectional 
study in two hospitals accredited Insurance, from March/2012 to May 2013 (n = 96 
patients). Data were recorded by medical (rheumatologist) in computerized manage-
ment system (Sabius ®) performed after the query. Later, these were entered into 
Microsoft Excell 2007 and analyzed by clinical pharmacists auditors. The cost was 
calculated from the unit value in the book Brasíndice 765, using the Consumer Price 
Maximum and average weight of 70 kg in standard doses. Results: Most patients 
were women (66, 68.75%), averaging 67 kg, aged between 30-59 years (62.50%) and 
higher incidence of rheumatoid arthritis among the diseases treated (45; 46.88%). 
The higher costs per capita were checked with Infliximab (R$ 62,459.40) and abata-
cept (R$ 41,989.55), while Adalimumab (R$ 16,614.60) and golimumab (R$ 10,385.05) 
represented the lowest cost per capita. There was a significant difference between 
the average cost per capita of IMB intravenous (91, R$ 48,975.27) and subcutaneous 
(11, R$ 10,695.49). The average cost for treatment / dose first line was R$ 6,068.91 
and the second line was R $ 9,590.06, resulting in an incremental cost / dose of R $ 
3,521.16 (36.72%). cOnclusiOns: The pharmacotherapeutic monitoring becomes 
important for planning strategies aimed at streamlining and optimization of these 
drugs and pharmacoeconomic clinical management.
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Objectives: Retrospective study to determine whether THR may be delayed by the 
use of US-guided Intra-articular injection (USGIAI) of hyaluronic acid (HA), in hip 
joint in patients affected by hip OA. MethOds: We evaluate the delaying in the 
THR considering 176 patients suffering from hip OA and treated with HA USGIAI, 
candidates for THR according to the judgment of six orthopaedics. Then, we imag-
ing two hypothetic populations of 1000 patients each candidates to THR, the first 
undergoing to 1 injection of HA (HyalOne-Hyalubrix 60) USGIAI and the second one 
undergoing to THR for a follow-up period of one year and four years. We performed 
the cost evaluation on hip surgery, eventual revision of the prosthesis, post-oper-
ative complications and mortality, rehabilitation, lost working days. Results: At 
24 months, 159 out of 76 (90 %) patients did not undergo to THR. At 48 months, 82 
% (N = 144) of the study population treated with HA USGIAI avoided THR. In the 
group of 93 patients candidates for THR (that is, in which 4, 5, or 6 orthopaedic 
surgeons agreed that the patient was a suitable candidate for THR), only 17 had 
undergone THR, with survival results of 82 % at 24 months. At 48 months, this 
percentage reduced to 66 % in this group. Results show that the treatment with 
HA USGIAI is the most favorable option, from a clinical and economic perspective, 
and also considering the social impact (higher value of quality-adjusted life-years 
(QALYs)). Analyzing hospital perspective, there are even higher benefits, estimated 
to be between approximately 940,000 euros in one year and 580,000 euros after 4 
years. cOnclusiOns: Data simulation comparing HA USGIAI vs THR in patients 
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Objectives: Several technologies are currently being developed for better 
stratifying individuals at risk of developing Rheumatoid Arthritis (RA) to patient-
tailored treatment. We assessed the potential cost-effectiveness of four technolo-
gies (MRI, il6-serum test, RNA B-cell signature, genetic assay) applied to patients 
with intermediate risk for RA (3-5 points on ACR/EULAR) using an one-year hori-
zon. MethOds: The cost-effectiveness was simulated with a decision model 
using data from the Rotterdam Early Arthritis Cohort (prevalence of RA: 55%). 
The comparator was 2010 ACR/EULAR classification criteria. Test properties (sen-
sitivity (se), specificity (sp) and costs) were based on literature and expert opinion. 
Patients were classified true positive (TP) if they score > = 6 points on the criteria 
or were test positive and used MTX at 12 months. True negative (TN) patients were 
those who that scored < 6 points or were test negative and did not use MTX at 
12 months. Utility changes within one year were assigned to TP (+0.1), TN (+0.1), 
false positive (+0.05), and false negative (-0.05). Results: RNA B-cell signature 
(se: 0.60; sp: 0.90; costs: € 150) has the largest net benefit (Δ TP-Δ FP) (45%) and is 
most cost-effective with an incremental cost effectiveness ratio (ICER) of € 13,939. 
The il-6 serum test (se 0.70; sp: 0.53; costs: € 100) has an ICER of € 17,343. The MRI 
and genetic assay have ICERs of € 38,541 and € 70,347 due to the higher incremen-
tal costs of these strategies. To stay below a willingness to pay (WTP) threshold 
of € 20,000/QALY gained (given current utility assumptions), the extra test costs 
of the new test strategy can maximally be € 230. cOnclusiOns: The RNA B-cell 
signature or il6-serum tests have most potential to be cost-effective in patients 
with intermediate risk of developing RA.
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Objectives: Rheumatoid arthritis is a progressive inflammatory disease that 
affects greatly patients’ quality of life and demands for aggressive manage-
ment early on during the course of the disease. The emergence of biologics has 
equipped rheumatologists with evolutionary treatment tools but it has also influ-
enced the costs of the disease, thus highlighting the necessity of cost-effective-
ness data. In this light, the purpose of this study was to conduct a systematic 
review of cost-effectiveness data for abatacept i.v. in the treatment of moderate 
to severe rheumatoid arthritis. MethOds: Pubmed, the International Society 
for Pharmacoeconomics and Outcomes Research Outcomes Research Digest, 
the National Health System Economic Evaluation Database, and the Database 
of Abstracts of Reviews of Effects were searched for papers published in the last 
decade (2002-2012). An initial search using the keywords “abatacept, cost effec-
tiveness, and rheumatoid arthritis” was followed by a search of related citations. 
The quality of independent economic evaluation studies was evaluated in accord-
ance to the Centre for Reviews and Dissemination set of guidelines. Results: In 
total 301 studies were identified and 42 met the inclusion criteria. The majority 
of rejected studies were due to lack of cost data, failure to include abatacept as 
a comparator to other biologic agents, and failure to include RA as a treatment 
indication. Half of the selected studies evaluated abatacept in the treatment 
of rheumatoid arthritis, after failure of or intolerance to tumor necrosis factor 
alpha inhibitors. Of those, 82% were in favor of abatacept as a cost-effective or 
dominant strategy versus varying alternatives, whereas 18% favored other treat-
ments. cOnclusiOns: The majority of evidence from the published literature 
supports that abatacept IV can be a cost-effective alternative in the treatment of 
moderate to severe rheumatoid arthritis.
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Objectives: To assess the cost-effectiveness of tocilizumab and TNF-alfa inhibi-
tors in the treatment of Russian patients with rheumatoid arthritis (RA) and 
intolerance or inadequate response to disease-modifying antirheumatic drugs 
(DMARDs) or for whom continuation of DMARDs was deemed inappropri-
ate. MethOds: Based on the data from ADACTA-trial and the results of indirect 
comparison of tocilizumab and anti-TNF-alfa agents (G. Bergman et al., 2010) 
two pharmacoeconomic models were developed. A six-month time horizon was 
adopted in the models. Cost-effectiveness of tocilizumab and adalimumab was 
estimated in the first model. In the second model, cost-effectiveness of toci-
lizumab was compared to the cost-effectiveness of antirheumatic therapy in 
the mixed treatment group, which included patients who received infliximab, 
etanercept and adalimumab in proportion 1:1:1. The cost analysis included 
costs of medicines and expenses for the day care services. The efficacy of the 
treatment was defined as a DAS28-reduction, proportion of patients achieved 
a low or moderate DAS28, EULAR good or moderate response (was considered 
only in the first model) and ACR20, ACR50, ACR70 responses. Sensitivity analysis 
(SA) was performed by changing costs of medicines and relative proportions of 
patients received infliximab, etanercept and adalimumab in the mixed treat-
ment group. Results: Despite the higher cost of treatment with tocilizumab 
(591,112.92 RUB as compared to 488,735.00 RUB for adalimumab), it had the bet-
ter cost-effectiveness ratios (CERs): 179,125.04 RUB vs 271,519.44 RUB per unit of 
DAS28-reduction, respectively. The similar results were observed for the CERs 
estimated per one patient with clinical response. Compared to the mixed treat-
ment group, tocilizumab also had better CERs. SA confirmed the robustness of 
the model. cOnclusiOns: The study has demonstrated that tocilizumab is an 
economically effective strategy in the treatment of Russian patients with RA 
and intolerance or inadequate response to DMARDs or for whom continuation 
of DMARDs was deemed inappropriate.
with the lowest total costs (437,620.24 RUB per one patient). The costs further 
increased in the row: etanercept (554,912.15 RUB), adalimumab (977,470.00 RUB), 
and infliximab (1,039,363.68 RUB). It should be noted that in the infliximab group 
the bulk of the costs (more than 60% of total) incurred within first six month of 
therapy. This may potentially increase the financial losses associated with inad-
equate response to infliximab. The estimated cost-effectiveness ratios (CERs) were 
241,779.14 RUB, 334,284.43 RUB, 630,625.81 RUB, and 670,557.21 RUB per unit of 
DAS28-reduction in the rituximab, etanercept, adalimumab and infliximab groups, 
respectively. The similar results were observed for the CERs estimated per one 
patient with EULAR good or moderate response (533,683.22 RUB, 730,147.57 RUB, 
1,286,144.74 RUB, and 1,367,583.79, respectively). SA demonstrated that results are 
robust. cOnclusiOns: The present study has demonstrated that administration 
of rituximab is economically effective strategy in the treatment of Russian patients 
with rheumatoid arthritis who failed previous anti-TNF-alfa therapy. Furthermore, 
treatment with rituximab is associated with considerably lower costs as compared 
to etanercept, adalimumab and infliximab.
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Objectives: Assess the cost-effectiveness of first-line tocilizumab bio-
logical treatment as monotherapy or in combination with methotrexate, in 
patients with rheumatoid arthritis (RA) refractory to treatment with non-
biological DMARDs. MethOds: A markov model was used of the natural his-
tory of RA to assess: tocilizumab, tocilizumab+methotrexate, adalimumab, 
adalimimab+methotrexate, etanercept, etanercept + methotrexate and 
infliximab+methotrexate. The systematic review of literature don’t show results 
for infliximab in monotherapy. The strategies were evaluated in combination with 
methotrexate in the first or second line, for a total of 11 strategies evaluated. 
Outcomes were measured as quality adjusted life years (QALYs). Analysis from 
the payer perspective, only direct costs were considered, COP 2012. Ratios were 
calculated cost-effectiveness and incremental cost-effectiveness, and sensitivity 
analyzes deterministic and probabilistic were conducted. For the RA chronicity, 
was used time horizon until life expectancy used discount rate of 3% for both costs 
and health outcomes. Results: Tocilizumab was one of the least expensive strat-
egy in first and second-line treatment. For life expectancy horizon monotherapy 
with tocilizumab followed by infliximab in second line are efficient frontier with 
an ICER per QALY gained of COP $165,918,610.58. The ICER is sensible to price 
of medicaments, with a inferiority limit, the results change to COP $106.160.64. 
The probabilistic analysis indicates that a threshold to willingness to pay of COP 
$ 150 million higher than monotherapy with tocilizumab, be cost-effective in 
Colombia. cOnclusiOns: The use of tocilizumab in first and second line like 
monotherapy and in combination strategy remains lower costs per benefit gained; 
in that sense, can be considered as an efficient therapy in the Colombian context.
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Objectives: The prognosis of rheumatoid arthritis (RA) has improved dramati-
cally with the development of tumour necrosis factor-alpha (TNFα ) inhibitors. 
However, some patients develop immunogenicity to TNFα inhibitors that can result 
in treatment failure and higher costs. In addition, immunogenicity to one TNFα 
inhibitor may create cross-resistance to others. Previous studies have shown the 
TNFα inhibitor etanercept (ETN) is less immunogenic than adalimumab (ADA) and 
infliximab (INF). The objective of this study was to determine the costs incurred 
due to the immunogenicity of ETN, ADA, and INF. MethOds: A Markov model 
was created using data from previously published studies (i.e. the proportions 
of patients developing antibodies against ADA and INF; the size of increase of 
dose or drug administration frequency in patients receiving ADA and INF if treat-
ment failed; and the rate of effective dose escalation in patients with and without 
immunogenicity) and from expert opinion (i.e. physician visit intervals). It was 
assumed that patients receiving ETN did not develop immunogenicity. Patients 
initially started ETN, ADA, or INF were allowed to switch treatment to a second 
or third TNFα inhibitor if treatment failed. Costs due to immunogenicity were 
calculated from: drug usage after treatment failure, dose or frequency increase 
after treatment failures, and additional visits due to lack of response. Results: 
Initiating treatment with ETN resulted in the highest proportion of patients still 
receiving first-line therapy after 5 years, compared with ADA or INF. Assuming 
15,000 patients (1% prevalence of RA in The Netherlands) treated for 5 years, 
the immunogenicity costs incurred with different sequential treatment strat-
egies were: ETN-ADA-INF € 4,937,176, ETN-INF-ADA € 5,409,593, ADA-ETN-INF 
€ 10,140,206, INF-ETN-ADA € 11,160,699, ADA-INF-ETN € 14,735,996, and INF-ADA-
ETN € 15,980,783. cOnclusiOns: The 5-year results of our model showed initiat-
ing treatment with ETN rather than ADA or INF resulted in higher adherence to 
first-line therapy and lower immunogenicity costs.
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